Seer (SEER) Stock Price

Seer Price

NASDAQ·CLOSED
1.68
​
Market closed

Revenue has compounded at 127.6% per year over the past 6 years to 16.12 M USD. Seer's net margin stands at -456.6%, up from -1,113.1% several years earlier. Analysts set a median price target of 3.06 USD, implying 82.1% above the current price. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.

Seer stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seer business model & stock analysis

Seer Inc is a company specializing in the development and marketing of advanced artificial intelligence (AI) technologies. It was founded in 2017 by Isaac J. Reyes and Bob L. Lowery, with its headquarters in San Diego, California. The story of Seer Inc began when Reyes and Lowery recognized a major need for solutions in automating processes, analyzing data, and processing large amounts of data. They saw the potential in AI technology to meet this need and founded Seer Inc to drive the development and marketing of AI-based products. Seer Inc's business model is based on providing customized AI-based solutions to meet the specific needs of its customers. The company develops and implements software solutions for a variety of industries, including biotechnology, healthcare, finance, and retail. Seer Inc ensures that its products are up-to-date by continuously investing in research and development. Seer Inc is divided into three main divisions – software development, data analysis, and AI research. The company's software development division is responsible for developing custom software applications and integrating AI technologies into existing systems. The data analysis division applies advanced analytical techniques to help customers translate data into valuable insights. The AI research division focuses on developing new AI technologies and algorithms to further enhance Seer Inc's products. The products currently offered by Seer Inc include a range of solutions, such as SoPhiA, an AI-based software used in biotechnology and pharmaceutical research to accelerate the development process of new therapeutics. Seer Inc also offers solutions for healthcare, including the development of personalized diagnosis and treatment options, as well as improving the patient experience through intelligent chatbots available 24/7. Additionally, Seer Inc develops AI-based solutions for financial service providers, retailers, and technology companies. Another important product of Seer Inc is the AI platform, which allows customers to develop and implement their own AI models and algorithms. This platform provides a user-friendly interface that enables companies to develop AI solutions without extensive IT knowledge. The platform also offers a wide range of tools and services, such as cloud hosting, data management, and model validation. Since its founding in a short time, Seer Inc has already received several awards and recognitions, such as the "AI Breakthrough Award" for its leading role in AI development. The company has also formed partnerships with leading companies and research institutions worldwide to make its products and services accessible globally. Overall, Seer Inc is a pioneering company that has had a tremendous impact on the technology industry with its vision and innovation in AI development. The company remains true to its values by advancing the development of technologies that improve people's lives and leverage the potential of artificial intelligence to solve complex problems.

Frequently asked questions about Seer

Seer Inc's business model revolves around developing and commercializing proprietary Proteograph™ technology to enable researchers in the life sciences field to gain deep insights into the proteome. By leveraging their expertise in mass spectrometry, data science, and bioinformatics, Seer Inc aims to revolutionize protein analysis and provide researchers with comprehensive insights into the proteome. With its innovative platform, Seer Inc offers powerful solutions to accelerate discoveries in various applications, such as drug discovery, diagnostics, and precision medicine. Through its cutting-edge technologies, Seer Inc strives to empower scientists and catalyze advancements in proteomics research.

Seer Inc is primarily active in the biotechnology and life sciences industries.

The main competitors of Seer Inc in the market include major players like Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation.

Seer Inc. is a leading life sciences company specializing in proteomics. Founded in 2017, the company aims to improve human health by enabling scientists to understand the dynamic world of biology through its innovative technologies. Seer's platform leverages the power of proteomics, a study of proteins, to provide deep insights into complex biological processes and diseases. Through its powerful proprietary technologies, Seer has gained recognition for its ability to analyze large-scale proteomic data sets accurately. With a team of experienced scientists and cutting-edge technology, Seer Inc. is poised to revolutionize the field of proteomics and contribute to advancements in healthcare.

Seer Inc, a leading company in the stock market, has achieved significant milestones in its journey. Notably, Seer Inc successfully completed its initial public offering (IPO), raising substantial capital to fuel its growth and expansion initiatives. The company has also received recognition for its breakthrough innovations and cutting-edge technologies in the field of stock trading. Furthermore, Seer Inc has successfully forged strategic partnerships with renowned industry players, strengthening its market position and enhancing shareholder value. With a strong commitment to delivering exceptional investment services, Seer Inc continues to revolutionize the stock market landscape, making it a highly promising investment option for individuals seeking sustainable financial growth.

Seer Inc is primarily present in the United States.

Seer Inc represents values of innovation, transparency, and collaboration. As a cutting-edge biotechnology company, Seer Inc operates with a corporate philosophy centered around advancing healthcare through transformative technologies. The company is committed to improving patient outcomes by developing novel solutions for understanding biology and enabling earlier disease detection. With a focus on data-driven insights and interdisciplinary approaches, Seer Inc fosters a culture of scientific excellence and teamwork. By aligning their vision with market needs, Seer Inc aims to revolutionize the field of proteomics and contribute to the future of precision medicine.

Analysts currently set an average price target of 3.06 USD for the Seer stock (median: 3.06 USD), implying +82.1 % versus the latest price. The consensus is based on 9 analyst ratings.

8 analysts currently rate the Seer stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Seer to generate revenue of 16.10 M USD and earnings per share of -1.10 USD.

Converted at the current exchange rate, the Seer share trades at 1.50 EUR (1.68 USD).

The Seer share (SEER) is listed on 1 stock exchanges, including: NASDAQ (SEER).

Seer Inc is a fast-growing company specializing in providing advanced imaging and diagnostic technology for the healthcare industry. The company started with the development of visualized data analytics and tools for data analysis and modeling, and has now expanded its activities to various sectors. One of the key sectors of Seer Inc is the development of computed tomography machines equipped with high-resolution scanners and powerful algorithms. These scanners are used in medical facilities such as hospitals and clinics to provide accurate and fast diagnoses and assist in surgical procedures. The company also offers solutions for mammography specifically designed for breast cancer prevention and diagnosis. Seer Inc mammography machines utilize advanced technologies such as digital image processing and layer imaging to provide accurate results without causing unnecessary radiation exposure to the patient. Seer Inc also offers advanced imaging products for molecular imaging. These products include in-vivo and in-vitro imaging systems tailored to various scientific applications and research areas. The company also collaborates closely with academic research institutions to develop innovative imaging solutions for intensive research and development in the healthcare industry. In addition to the aforementioned products and sectors, Seer Inc also provides technical services to its customers, including maintenance and repair services. The company is committed to providing comprehensive and reliable support to its customers to ensure the maximum lifespan of the products and ensure the highest level of patient care. The business model of Seer Inc is driven by its focus on continuous innovation and research. The company is always striving to develop new technologies and products to better meet the needs of its customers and improve healthcare worldwide. Seer Inc works closely with leading research institutions and medical professionals to ensure that its products meet the highest standards and meet the needs of patients and medical professionals. Overall, Seer Inc is a leading company in the healthcare industry, offering innovative imaging solutions for a variety of applications and research areas. The company is dedicated to providing excellent service and top-notch products to its customers to ensure the highest quality of patient care and advance the healthcare industry worldwide.

The expected revenue of Seer is 16.10 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Seer is -63.19 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Seer is currently -1.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Seer stock.

The price-to-sales ratio (P/S) of Seer is currently 5.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Seer stock.

The Eulerpool Quality Score for Seer is 2/10.

The ISIN of Seer is US81578P1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Seer is SEER. The ticker symbol is used to trade Seer shares on the stock exchange.

Fair ValueTerminal
1.48 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
136,601.69 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website seer.bio
Currency
USD
Initial public offering
Dec 4, 2020
ISIN
US81578P1066
Cusip
81578P106
Sedol
BMCWDS6
Market capitalization
96.51 M USDMicro Cap
52-Week Range
PEG
0.06
P/E ratio
P/Ee 2026
-1.53
P/Ee 2027
-1.59
P/Ee 2028
-1.93
P/Ee 2029
-2.30
P/Ee 2030
-5.25
P/S
P/Se
5.99
EV/EBIT
—
P/B Ratio
0.37
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.01 %
Last updated Nov 3, 2026, 2:15 PM

Seer Peer Group

Seer Ticker

NASDAQ · SEER

Seer FIGI

SEER:US · BBG00HPLTRR8SEER:UA · BBG00Y62MW90SEER:UC · BBG00Y62MWB7SEER:UN · BBG00Y62MWD5SEER:UP · BBG00Y62MWF3SEER:UB · BBG00Y62MWH1SEER:UM · BBG00Y62MWK7SEER:UX · BBG00Y62MWL6SEER:UD · BBG00Y62MWR0SEER:UW · BBG00Y62MWT8SEER:UF · BBG00Y62MWV5SEER:VY · BBG00Y62MWW4

All fundamentals and in-depth analysis of Seer

Our stock analysis for Seer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.